Loading…

Unmet therapeutic goals and potential treatable traits in a population of patients with severe uncontrolled asthma in Spain. ENEAS study

[Display omitted] -We have added the following highlights:•It seems reasonable to approach asthma heterogeneity pragmatically, setting specific therapeutic goals for each individual and associating them with treatable traits.•The most common clinical phenotype was late-onset eosinophilic asthma (58....

Full description

Saved in:
Bibliographic Details
Published in:Respiratory medicine 2019-05, Vol.151, p.49-54
Main Authors: Pérez de Llano, Luis, Martínez-Moragón, Eva, Plaza Moral, Vicente, Trisan Alonso, Andrea, Sánchez, Carlos Almonacid, Callejas, Francisco Javier, Vera, Elisabeth, Soto Campos, Jose Gregorio, Martinez Rivera, Carlos, Alcázar Navarrete, Bernardino, Urrutia Landa, Isabel, Garcia Rivero, Juan Luis, Padilla Galo, Alicia, Alvarez Gutierrez, Francisco, Landete, Pedro, Ramos González, Jacinto, Aracil, Cleofé Fernández, Carretero Gracia, José Ángel, Lluch, Inmaculada, Puente, Luis, Andujar-Espinosa, Ruben, Cosío, Borja Garcia
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:[Display omitted] -We have added the following highlights:•It seems reasonable to approach asthma heterogeneity pragmatically, setting specific therapeutic goals for each individual and associating them with treatable traits.•The most common clinical phenotype was late-onset eosinophilic asthma (58.1%) in a population of adult uncontrolled severe asthmatics.•More than half of the patients had not experienced severe exacerbations in the previous year and the most common therapeutic objective was symptom control (71% of the cases).•From a set of serum biomarkers (IgE, IL-5, IL-13, periostin, CCL23, Il-6, IL-8, IL-17, TNFα and IFNγ) only IL-8 was found to be significantly associated with a therapeutic goal: uncontrolled symptoms.
ISSN:0954-6111
1532-3064
DOI:10.1016/j.rmed.2019.03.006